Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Conference Call Takeaways

Article Stock Quotes (1) Comments (0)

Needham & Company reiterates a 'Buy' on Lexicon Pharmaceuticals (NASDAQ: LXRX) price target of $3.00.

Analyst, Alan Carr, said, "Lexicon management provided a quarterly update in a conference call yesterday. The company reported positive top-line results from its Phase 2b trial of LX4211 in type 2 diabetes in June 2012 and is now seeking a partner. Data available thus far suggest that the drug is well-differentiated...Upcoming news flow, including results from multiple proof-of-concept Phase 2 trials expected in 3Q12, may provide upside for the stock over the next few months."

For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.

Shares of Lexicon Pharmaceuticals closed at $2.42 yesterday, with a 52 week range of $0.81-$3.28.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
• Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
• Wells Fargo Starts Taylor Morrison Home (TMHC) at Outperform

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?